Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of $431,903.8861 in Common Shares
Bitget2026/11/04 22:24- Nurix Therapeutics Chief Legal Officer Christine Ring sold 16,715 common shares on Nov. 2-3, 2026
- Nov. 2 sales comprised 9,527 shares at $25.7392 per share; another 1,075 shares sold at $26.7628
- The Nov. 3 sale totaled 6,113 shares at $25.8329 per share
- Ring also exercised employee stock options for 5,786 common shares at $8.72 per share on Nov. 2
- Direct common stock holdings stood at 4,406 shares following the transactions, according to the Form 4 dated Nov. 4, 2026
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

BoE’s Greene says it is appropriate to proactively tighten our monetary policy stance

CoreWeave plans to issue at least $4 billion in investment-grade loans, falling nearly 6% after hours
According to Bloomberg, CoreWeave is seeking to refinance at least 4 billion USD through an investment-grade loan, led by Morgan Stanley and Mitsubishi UFJ, with a syndication roadshow expected to start as soon as next week. This financing continues the structure of using Nvidia chips and customer contracts as collateral, with the yield on the issuance anticipated to be around 7% to 7.5%, much lower than its junk bond yield. Following the news, CoreWeave's shares fell nearly 5.8% after hours.

Outperformed the S&P by 19.2 percentage points in one month: Berkshire (BRK.B) achieves its highest monthly relative advantage since 2010, second only to the 2008 financial crisis
As the AI trading boom subsides and technology stocks waver, one of the market’s oldest “safe havens” has once again proven its value. Berkshire Hathaway (BRK.B) has just recorded one of its most notable relative gains in over a decade.